Zeta S100P Antibody. Zeta’s recombinant rabbit antibody recognizes S100P, a protein shown to mediate tumor growth, metastasis, and invasion through the binding of Ca2+ ions, the receptor for advanced glycation end products, cytoskeletal protein ezrin, calcyclin-binding protein/Siah-1-interacting protein, and cathepsin D.
S100P is a 95-amino-acid protein and a member of the S100 family and may initiate carcinogenesis in some epithelial tumors. Intracellular S100P interacts with ezrin, and extracellular S100P activates the receptor for advanced glycation end products. S100P highly expressed in human placenta, gastrointestinal tract, and esophageal mucosa, but always negative in pancreas and liver. Overexpression of S100P has been detected in several cancers such as breast, colon, prostate, pancreatic, and lung carcinomas, and the protein has been functionally implicated in carcinogenic processes. S100P could serve as a diagnostic marker, prognostic/predictive indicator, and therapeutic target for different carcinomas.
S100P is associated with aggressive disease in peripheral intrahepatic cholangiocarcinoma; pancreatic adenocarcinoma in FNA specimens; and differentiate urothelial carcinoma (S100P+) from prostatic adenocarcinoma (S100P-). Finally, S100P can help differentiate bile duct adenocarcinoma from reactive lesions at biopsy, as part of a immunohistochemical panel with pVHL and IMP3.